Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGM0504 in Overweight or Obese Participants Without Diabetes
NCT07658560Phase 2Recruiting
- Sponsor
- BrightGene Bio-Medical Technology
- Start
- Jun 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BGM0504 in obesity (5 arms), sponsored by BrightGene Bio-Medical Technology. Primary endpoint: Fasting body weight at 20 weeks. Started Jun 2026; status: recruiting.
02
Drugs
BGM0504
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07658560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07658560.